Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1.
about
A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGDRegistered report: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugsThe effect of superparamagnetic iron oxide with iRGD peptide on the labeling of pancreatic cancer cells in vitro: a preliminary study.A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.Tumor penetrating peptides for improved drug delivery.Tumor-Penetrating Nanoparticles for Enhanced Anticancer Activity of Combined Photodynamic and Hypoxia-Activated Therapy.Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC.NRP1 transport of cancer therapeutics mediated by tumor-penetrating peptides.Tumour tissue transport after intraperitoneal anticancer drug delivery.Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles.Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL?An Updated Review on Marine Anticancer Compounds: The Use of Virtual Screening for the Discovery of Small-Molecule Cancer Drugs.Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer.Tumor-Penetrating Nanosystem Strongly Suppresses Breast Tumor Growth.iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.Competition of charge-mediated and specific binding by peptide-tagged cationic liposome-DNA nanoparticles in vitro and in vivo.Access granted: iRGD helps silicasome-encased drugs breach the tumor barrier.Jack of many trades: Multifaceted role of neuropilins in pancreatic cancer
P2860
Q28548244-0493A5CB-E7F8-41CB-98B4-130B714789D3Q28647159-83DEDBA5-40CD-45D5-87E1-78237AF976E1Q33746572-954A2154-4D4A-4EF5-A17F-2A8541517726Q35868066-AAB95BAD-95ED-4808-BCC3-5A309813E584Q35978545-21F8CC07-8650-486A-A11C-0D081A3661FFQ36271313-1F0A0599-3C5C-43D0-8EBE-F172B4B88164Q37406885-0761E298-1C10-4279-8B3B-344992A63E62Q38672213-468714B3-E094-491B-9D39-D07A73D60861Q38679465-2F11B6A9-672F-4F02-BC12-293E6CB05571Q38731251-0281AC0C-AF39-4CDE-9377-E95F30D7247BQ38862473-D45CE948-75E9-438A-B9EB-73BE3563286EQ39394159-9BFE9944-FF09-4D35-B600-237191AECEA3Q42290164-92CFAB1A-E8D1-4422-9E57-369BE7EC8225Q46039070-A706C37A-D06C-48A0-B19C-D9E911CE3F24Q46505275-1AAE84E3-ECD6-44BC-BCDD-2F47F8FD85E8Q52653896-1DEEF4BA-523B-42C0-BE22-54465C808A33Q54915254-9836530B-22CB-433C-98A6-204510F4BC54Q58738114-6C6D3D55-8569-4525-9422-44D17488F12B
P2860
Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anticancer effects of gemcitab ...... at overexpressed neuropilin-1.
@en
Anticancer effects of gemcitab ...... at overexpressed neuropilin-1.
@nl
type
label
Anticancer effects of gemcitab ...... at overexpressed neuropilin-1.
@en
Anticancer effects of gemcitab ...... at overexpressed neuropilin-1.
@nl
prefLabel
Anticancer effects of gemcitab ...... at overexpressed neuropilin-1.
@en
Anticancer effects of gemcitab ...... at overexpressed neuropilin-1.
@nl
P2093
P2860
P356
P1476
Anticancer effects of gemcitab ...... hat overexpressed neuropilin-1
@en
P2093
N Ohkohchi
S Hashimoto
P2860
P2888
P304
P356
10.1038/BJC.2014.49
P407
P577
2014-02-20T00:00:00Z